Decibel Therapeutics (NSDQ:DBTX) recently presented preclinical data for DB-OTO at the Annual MidWinter Meeting of the Association for Research in Otolaryngology (ARO). DB-OTO is a dual-vector adeno-associated virus (AAV) investigational gene therapy product candidate for individuals with hearing loss from mutations of the otoferlin gene. The most recent data showed that otoferlin expression increased for…
Decibel Therapeutics announces study on noise-related inner ear damage
Decibel Therapeutics (NSDQ:DBTX) has a working hypothesis that molecular characterization of the cell biology of the inner ear could pave the way for treatments for hearing and balance disorders. The Boston-based biotech company has announced that a recent study published in Cell Reports supports that hypothesis. “We were thrilled to leverage our data and expertise in inner…